Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTA NASDAQ:INDV NASDAQ:KOD NASDAQ:NAMS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTACentessa Pharmaceuticals$23.23+0.8%$19.12$9.60▼$24.57$3.11B1.571.48 million shs1.01 million shsINDVIndivior$23.17-0.4%$23.00$7.33▼$25.10N/A0.72.45 million shs1.17 million shsKODKodiak Sciences$15.06+12.1%$10.24$1.92▼$19.39$795.50M2.671.08 million shs649,604 shsNAMSNewAmsterdam Pharma$30.67-0.1%$25.25$14.06▼$31.81$3.45B0.021.06 million shs966,020 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTACentessa Pharmaceuticals0.00%-0.13%+47.12%+62.05%+42.87%INDVIndivior0.00%-3.14%-6.31%+44.05%+131.47%KODKodiak Sciences0.00%-4.68%+76.14%+280.30%+474.81%NAMSNewAmsterdam Pharma0.00%+7.61%+19.52%+54.55%+75.96%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTACentessa Pharmaceuticals$23.23+0.8%$19.12$9.60▼$24.57$3.11B1.571.48 million shs1.01 million shsINDVIndivior$23.17-0.4%$23.00$7.33▼$25.10N/A0.72.45 million shs1.17 million shsKODKodiak Sciences$15.06+12.1%$10.24$1.92▼$19.39$795.50M2.671.08 million shs649,604 shsNAMSNewAmsterdam Pharma$30.67-0.1%$25.25$14.06▼$31.81$3.45B0.021.06 million shs966,020 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTACentessa Pharmaceuticals0.00%-0.13%+47.12%+62.05%+42.87%INDVIndivior0.00%-3.14%-6.31%+44.05%+131.47%KODKodiak Sciences0.00%-4.68%+76.14%+280.30%+474.81%NAMSNewAmsterdam Pharma0.00%+7.61%+19.52%+54.55%+75.96%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTACentessa Pharmaceuticals 2.91Moderate Buy$32.3839.37% UpsideINDVIndivior 3.00Buy$22.00-5.05% DownsideKODKodiak Sciences 2.00Hold$13.00-13.68% DownsideNAMSNewAmsterdam Pharma 2.70Moderate Buy$42.0036.94% UpsideCurrent Analyst Ratings BreakdownLatest KOD, INDV, NAMS, and CNTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025CNTACentessa PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025INDVIndiviorWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)9/27/2025KODKodiak SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025NAMSNewAmsterdam PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/25/2025KODKodiak SciencesBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Equal Weight$7.00 ➝ $17.009/22/2025KODKodiak SciencesJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$15.009/3/2025CNTACentessa PharmaceuticalsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/3/2025CNTACentessa PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$31.008/29/2025CNTACentessa PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$40.008/27/2025INDVIndiviorCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$27.00 ➝ $34.008/25/2025NAMSNewAmsterdam PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$45.00(Data available from 10/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTACentessa Pharmaceuticals$6.85M454.12N/AN/A$3.05 per share7.62INDVIndivior$1.19BN/A$1.82 per share12.73($2.52) per shareN/AKODKodiak SciencesN/AN/AN/AN/A$2.86 per shareN/ANAMSNewAmsterdam Pharma$45.56M75.82N/AN/A$8.20 per share3.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTACentessa Pharmaceuticals-$235.76M-$1.79N/AN/AN/AN/A-40.39%-29.87%11/11/2025 (Estimated)INDVIndivior$2M$0.6237.3713.55N/A6.65%-86.28%16.26%10/23/2025 (Estimated)KODKodiak Sciences-$176.21M-$3.80N/AN/AN/AN/A-155.27%-63.29%11/13/2025 (Estimated)NAMSNewAmsterdam Pharma-$241.60M-$1.62N/AN/AN/A-259.07%-27.27%-25.00%11/5/2025 (Estimated)Latest KOD, INDV, NAMS, and CNTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/23/2025Q3 2025INDVIndivior$0.38N/AN/AN/AN/AN/A8/13/2025Q2 2025KODKodiak Sciences-$1.01-$1.03-$0.02-$1.03N/AN/A8/12/2025Q2 2025CNTACentessa Pharmaceuticals-$0.35-$0.38-$0.03-$0.38$0.63 millionN/A8/6/2025Q2 2025NAMSNewAmsterdam Pharma-$0.52-$0.15+$0.37-$0.15$1.44 million$19.15 million7/31/2025Q2 2025INDVIndivior$0.26$0.51+$0.25$0.14$239.43 million$302.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNTACentessa PharmaceuticalsN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTACentessa Pharmaceuticals0.3210.1110.12INDVIndiviorN/A0.900.76KODKodiak SciencesN/A3.483.48NAMSNewAmsterdam PharmaN/A21.0821.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTACentessa Pharmaceuticals82.01%INDVIndivior60.33%KODKodiak Sciences89.06%NAMSNewAmsterdam Pharma89.89%Insider OwnershipCompanyInsider OwnershipCNTACentessa Pharmaceuticals7.09%INDVIndiviorN/AKODKodiak Sciences45.90%NAMSNewAmsterdam Pharma20.84%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTACentessa Pharmaceuticals200133.91 million124.42 millionOptionableINDVIndivior1,051N/AN/ANot OptionableKODKodiak Sciences9052.82 million28.58 millionOptionableNAMSNewAmsterdam Pharma4112.63 million89.16 millionOptionableKOD, INDV, NAMS, and CNTA HeadlinesRecent News About These CompaniesNewAmsterdam Pharma (NASDAQ:NAMS) Reaches New 12-Month High - Here's What HappenedOctober 2 at 4:49 AM | marketbeat.comAnalysts Set NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Price Target at $42.00September 30, 2025 | americanbankingnews.comNewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Average Recommendation of "Moderate Buy" by BrokeragesSeptember 27, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Sets New 1-Year High - Here's What HappenedSeptember 26, 2025 | marketbeat.comNewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic ForumSeptember 24, 2025 | globenewswire.comAtle Fund Management AB Raises Holdings in NewAmsterdam Pharma Company N.V. $NAMSSeptember 21, 2025 | marketbeat.comJames Topper Buys 660 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) StockSeptember 18, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Director James Topper Buys 660 SharesSeptember 18, 2025 | insidertrades.comPTM Wealth Management LLC Takes $256,000 Position in NewAmsterdam Pharma Company N.V. $NAMSSeptember 16, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Sets New 12-Month High - Time to Buy?September 14, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Sees Unusually-High Trading Volume on Insider Buying ActivitySeptember 13, 2025 | marketbeat.comFred Alger Management LLC Has $561,000 Stock Holdings in NewAmsterdam Pharma Company N.V. $NAMSSeptember 13, 2025 | marketbeat.comLouise Frederika Kooij Sells 150,000 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) StockSeptember 12, 2025 | marketbeat.comInsider Buying: NewAmsterdam Pharma (NASDAQ:NAMS) Director Purchases 1,260 Shares of StockSeptember 12, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Director Acquires $31,487.40 in StockSeptember 11, 2025 | insidertrades.comWoodline Partners LP Purchases 11,615 Shares of NewAmsterdam Pharma Company N.V. $NAMSSeptember 11, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Down 9.7% Following Insider SellingSeptember 10, 2025 | marketbeat.comAlliancebernstein L.P. Has $45.89 Million Position in NewAmsterdam Pharma Company N.V. $NAMSSeptember 9, 2025 | marketbeat.comParkman Healthcare Partners LLC Purchases 24,839 Shares of NewAmsterdam Pharma Company N.V. $NAMSSeptember 8, 2025 | marketbeat.comTrexquant Investment LP Purchases New Position in NewAmsterdam Pharma Company N.V. $NAMSSeptember 8, 2025 | marketbeat.comDuquesne Family Office LLC Grows Stock Holdings in NewAmsterdam Pharma Company N.V. $NAMSSeptember 6, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKOD, INDV, NAMS, and CNTA Company DescriptionsCentessa Pharmaceuticals NASDAQ:CNTA$23.23 +0.18 (+0.78%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$23.17 -0.06 (-0.26%) As of 10/3/2025 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.Indivior NASDAQ:INDV$23.17 -0.09 (-0.39%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$23.17 0.00 (0.00%) As of 10/3/2025 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Kodiak Sciences NASDAQ:KOD$15.06 +1.63 (+12.14%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$14.58 -0.48 (-3.19%) As of 10/3/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.NewAmsterdam Pharma NASDAQ:NAMS$30.67 -0.03 (-0.10%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$30.74 +0.07 (+0.23%) As of 10/3/2025 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? Starbucks Stock Slumps; This Competitor Shows Strength How Berkshire's OxyChem Buy Cements Its Long-Term Strength The Trade Desk: 2 Signs of a Comeback, 1 Risk Ahead NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
